Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group.

@article{Patel1997ValaciclovirFT,
  title={Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group.},
  author={R Patel and Neil J. Bodsworth and P. D. Woolley and Brian Peters and Gunhild Lange Vejlsgaard and Seppo Saari and A Gibb and J. Robinson},
  journal={Genitourinary Medicine},
  year={1997},
  volume={73},
  pages={105 - 109}
}
OBJECTIVE: To determine the efficacy and safety of once daily valaciclovir for the suppression of recurrent genital herpes simplex virus (HSV) infection in immunocompetent patients. METHODS: 382 otherwise healthy patients with a history of frequently recurring genital HSV infection (eight recurrences per year) were randomly allocated to receive either oral valaciclovir (500 mg once daily) or placebo (3:1 ratio) for 16 weeks or until the first genital HSV recurrence, whichever occurred first… 

Tables from this paper

Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.

TLDR
Valaciclovir is well tolerated at dosages used to suppress recurrent episodes of genital herpes in immunocompetent and HIV seropositive individuals, with headache being reported most often.

Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group.

TLDR
Valaciclovir is highly effective and well tolerated for suppression of recurrent genital herpes and once-daily regimens offer a useful option for patients who require suppressive therapy for management of genital herpes.

Oral Famciclovir for the Suppression of Recurrent Genital Herpes: The Combined Data from Two Randomized Controlled Trials

TLDR
Oral famciclovir 250 mg twice daily is an effective, well-tolerated treatment for the suppression of genital HSV infection in patients with frequent recurrences and was well tolerated, with an adverse-experience profile comparable with placebo.

Oral Famciclovir for the Suppression of Recurrent Genital Herpes: The Combined Data from Two Randomized Controlled Trials

TLDR
Oral famciclovir 250 mg twice daily is an effective, well-tolerated treatment for the suppression of genital HSV infection in patients with frequent recurrences and was well tolerated, with an adverse-experience profile comparable with placebo.

Imiquimod 5-Percent Cream Does Not Alter the Natural History of Recurrent Herpes Genitalis: a Phase II, Randomized, Double-Blind, Placebo-Controlled Study

TLDR
No apparent effect on the short-term natural history of herpes genitalis recurrences was observed and a trend in increased rates of local adverse events at the application site and a delay in lesion healing with more frequent dosing suggested a pharmacologic effect.

Once-daily valacyclovir to reduce the risk of transmission of genital herpes*

TLDR
Once-daily suppressive therapy with valacyclovir significantly reduces the risk of transmission of genital herpes among heterosexual, HSV-2-discordant couples.

Valacyclovir. New indication: for genital herpes, simpler administration.

  • Medicine
    Canadian family physician Medecin de famille canadien
  • 1999
TLDR
The efficacy of valacyclovir (500 mg/d in a single dose) has been proven in a placebo-controlled trial lasting 4 months and the clinical file is bulky and methodologically sound, with no major differences between the two drugs.

Treatment to prevent recurrent genital herpes

TLDR
Control of herpes recurrence remains an important goal because of the impact it has on the quality of life of millions of people and its relationship with transmission of other sexually transmitted diseases, especially HIV infection.
...

References

SHOWING 1-10 OF 34 REFERENCES

Oral acyclovir suppressive therapy in severe recurrent genital herpes. A double-blind, placebo-controlled cross-over study.

TLDR
Acyclovir prophylaxis of recurrent genital herpes is effective and safe and a continuous suppressive therapy with acyclovir offers a basis for a normal sexual life to patients severely incapacitated by their disease, but once medication is stopped, patients shed virus as before suppression.

Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial.

TLDR
Normal adults with six or more episodes of genital herpes in the previous year were enrolled in a one-year, multicenter, double-blind trial comparing placebo with 400 mg of acyclovir administered orally twice daily; this allowed comparison of suppressive and episodic treatment.

A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection.

TLDR
It is concluded that oral acyclovir given for four months markedly reduces but does not completely prevent recurrences of genital herpes and does not influence the long-term natural history of the disease.

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults

TLDR
In the management of immunocompetent patients aged > or = 50 years of age with localized herpes zoster, valaciclovir given at 1,000 mg three times daily for 7 days accelerates the resolution of pain and offers simpler dosing, while it maintains the favorable safety profile of acyclovir.

Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

TLDR
Oral aciclovir has prevented recurrence of HSV genital or orofacial infections during suppressive therapy in > 70% of immunocompetent patients in most clinical trials and appears to offer partial protection from invasive CMV disease in CMV-seropositive bone marrow transplant recipients.

Oral acyclovir for episodic treatment of recurrent genital herpes. Efficacy and safety.

Oral acyclovir in the treatment of herpes zoster in general practice.

TLDR
Acyclovir reduced the extent and duration of the rash, the spread of the Rash to adjacent dermatomes and the incidence of disseminated lesions, and it shortened the period of new lesion formation and reduced the occurrence of ulceration in acute herpes zoster and postherpetic neuralgia.

A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group.

TLDR
This study provides the first convincing demonstration that antiviral therapy can prevent lesion development and should prompt a reconsideration of the role that episodic treatment plays in the management of recurrent herpes genitalis.

Therapy of herpes zoster with oral acyclovir.

TLDR
In a six-month follow-up of recipients in the higher dosage study, the acyclovir recipients experienced less post-zoster pain than placebo recipients; differences in the prevalence of pain were most significant for the presence of a persistent pain in the first three months of follow- up.